Regorafenib (monohydrate) (Standard)

Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate) . This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity[1].

Product Specifications

CAS Number

[1019206-88-2]

Product Name Alternative

BAY 73-4506 (monohydrate) (Standard)

UNSPSC

12352005

Target

Autophagy; c-Kit; FGFR; PDGFR; Raf; Reference Standards; RET; Tie; VEGFR

Type

Reference Standards

Related Pathways

Autophagy; MAPK/ERK Pathway; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/regorafenib-monohydrate-standard.html

Smiles

O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F.O

Molecular Formula

C21H17ClF4N4O4

Molecular Weight

500.83

References & Citations

[1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2 (1), 39-49.|[3]Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.